1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Children's Minnesota is a company with 1 orphan drug designation across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell acute lymphoblastic leukemia | humanized IgG1 monoclonal VpreB1 antibody conjugated to N-acetyl gamma-calicheamicin 1, 2-dimethyl hydrazine dichloride (NAc gamma-calicheamicin DMH) via an acid-labile 4-(4-acetylphenoxy) butanoic acid linker (acetyl butyrate) | Des.TrialAppr. |
| acute lymphoblastic leukemia | humanized IgG1 monoclonal VpreB1 antibody conjugated to N-acetyl gamma-calicheamicin 1, 2-dimethyl hydrazine dichloride (NAc gamma-calicheamicin DMH) via an acid-labile 4-(4-acetylphenoxy) butanoic acid linker (acetyl butyrate) | Des.TrialAppr. |
| precursor B-cell acute lymphoblastic leukemia | humanized IgG1 monoclonal VpreB1 antibody conjugated to N-acetyl gamma-calicheamicin 1, 2-dimethyl hydrazine dichloride (NAc gamma-calicheamicin DMH) via an acid-labile 4-(4-acetylphenoxy) butanoic acid linker (acetyl butyrate) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio